Enfortumab Vedotin Sustains OS Benefit in Locally Advanced or Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv resulted in a significant improvement in overall survival versus chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who received prior treatment with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.
Experts Consider Long-Term Impact of COVID-19 Pandemic on Oncology Care
September 13th 2020As the impact of the coronavirus disease 2019 pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.
COVID-19 Crisis Results in Increased Risk of Distress, Burnout Among Oncology Professionals
The wellbeing and job performance of oncology professionals has been significantly impacted by the COVID-19 pandemic, and although the extent of this impact is varied between countries, it has been suggested to be related to the crude mortality rate of the virus.
Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.
Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC
Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.
Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers
Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.
Ripretinib Shows Dramatic PFS Improvement for Heavily Pretreated GIST
Treatment with the novel KIT and PDGFRA inhibitor ripretinib reduced the risk of progression or death by 85% compared with placebo for heavily pretreated patients with advanced gastrointestinal stromal tumors, according to findings from the phase III INVICTUS trial presented at the ESMO Congress 2019.
Trametinib Emerges as New Standard Option for Recurrent, Low-Grade Ovarian Cancer
Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.
Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer
Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.
Entrectinib Delivers Durable Responses in ROS1+, NTRK+ Lung Cancer
Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.
Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC
Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.
Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer
A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.
Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer
September 30th 2019The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.
Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC
Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.
Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers
The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.
Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer
September 29th 2019Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.
An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.
Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer
September 29th 2019The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.
Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer
With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.
Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer
Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.